Nordson (NDSN) Q1 2026 earnings review
Semiconductor Cycle Ignites Record Q1, Guidance Raised
Nordson kicked off FY26 with record first-quarter sales of $669M (+9% YoY), driven by a powerful inflection in the Advanced Technology Solutions (ATS) segment and a return to growth in Industrial Precision Solutions (IPS). The semiconductor and electronics recovery lifted ATS organic sales by 21%, validating management's prior optimism about the cycle. Adjusted EPS rose 15% to $2.37. Consequently, management raised full-year guidance, now seeing FY26 revenue between $2.86B and $2.98B. However, profitability trends were mixed: while Medical margins surged on portfolio moves, Industrial margins compressed significantly.
🐂 Bull Case
The ATS segment, a proxy for semiconductor and electronics capex, surged 23% YoY (21% organic). Order entry momentum in electronics dispense and x-ray systems confirms the industry has turned the corner, with Asia Pacific sales jumping 25%.
Unlike late FY25, where growth was uneven, Q1 saw organic sales growth across all three segments. Even the struggling Industrial segment (IPS) flipped from negative to positive (+3% organic), suggesting the industrial trough is past.
🐻 Bear Case
While IPS revenue recovered, its quality deteriorated. IPS EBITDA margin fell 380 basis points YoY to 33.7%, likely due to mix shifts or lingering inflation, diluting the impact of the volume recovery.
Geographic divergence is stark. While Asia boomed, Americas sales declined 2.2% YoY (organic -0.4%). Strength in export-oriented Asian manufacturing is masking domestic sluggishness.
⚖️ Verdict: 🟢
Bullish. The re-acceleration in ATS is the headline story, confirming Nordson is a prime beneficiary of the AI/electronics capex wave. The return to organic growth in IPS removes a major drag, although margin compression there bears watching. Raised guidance signals confidence.
Key Themes
Advanced Technology Solutions (ATS) Inflection
ATS has decisively exited its slump. Sales grew 23% YoY to $149M, with organic growth of 21%. This marks a sharp acceleration from the -4% decline seen in 25Q4. Drivers include robust demand for electronics dispense systems (packaging) and a recovery in x-ray systems. EBITDA margin in the segment expanded to 22% from 19% a year ago, demonstrating strong operating leverage on volume recovery.
Industrial Precision Solutions (IPS) Profitability Dip
The Industrial segment grew revenue 9% YoY (3% organic), breaking a streak of declines. However, profitability went the wrong way. EBITDA dropped to $110M from $113M a year ago, causing margin compression from 37.5% to 33.7%. This divergence suggests that the volume recovery is coming from lower-margin product lines or that cost pressures remain sticky.
Medical Segment Repositioning Pays Off
Medical and Fluid Solutions (MFS) reported flat sales ($193M) due to the 4% headwind from divesting the medical contract manufacturing business. However, the strategy to shed low-margin revenue is working: segment EBITDA margin expanded to 36% from 33% last year. Organic growth was +3%, driven by engineered fluid solutions, signaling underlying health in the remaining portfolio.
Asia Pacific Leading Geographic Growth
Regional performance was heavily skewed towards Asia, which grew 25% YoY to $225M. This correlates with the semiconductor/electronics strength. In contrast, Americas declined 2% and Europe grew 9%. This geographic mix likely supported the ATS surge but may explain some of the IPS margin dynamics if regional pricing/mix varies.
Backlog Accumulation
Backlog increased 4% YoY, supporting the raised full-year guidance. Management cited broad-based order entry momentum, particularly in ATS, positioning the company for a strong Q2.
Other KPIs
Record first-quarter EBITDA, up 8% YoY. While absolute dollars grew, the margin compressed slightly to 30.3% from 30.6% a year ago, driven primarily by the IPS segment weakness.
Down from $159M in the prior year period. The decline occurred despite higher net income, driven by changes in operating assets and liabilities (-$18M vs +$24M prior year), suggesting some working capital build to support the ramping ATS revenue.
Up 15% from $2.06 in 25Q1. Note: GAAP EPS was $2.38, benefiting from a non-cash gain on a minority investment. Adjusted EPS excludes this gain and acquisition amortization, providing a cleaner view of operational leverage.
Guidance
Stable/Accelerating. The midpoint ($725M) implies ~6% YoY growth vs $683M in 25Q2. Sequentially, this represents a normal seasonal step-up from Q1's $669M.
Accelerating. Midpoint ($2.80) implies ~16% growth over 25Q2's $2.42, suggesting confidence that margin pressures in IPS may stabilize or be offset by ATS volume leverage.
Increased. Management raised the full-year outlook based on the strong Q1 start. The midpoint ($2.92B) implies ~4.6% annual growth, an improvement over the roughly flat/low-single digit performance of FY25.
Increased. Raised from prior expectations. Midpoint ($11.30) implies ~10% growth over FY25's $10.24, signaling a return to the company's long-term double-digit earnings growth algorithm.
Key Questions
IPS Margin Compression Causes
IPS margins dropped 380 basis points YoY despite 9% sales growth. Is this due to product mix (less aftermarket?), temporary manufacturing inefficiencies, or pricing pressure in industrial markets?
Americas Weakness vs Asia Strength
With Americas revenue down 2.2% while Asia surged, what specific end markets in North America are dragging? Is this automotive-related, and do you see a recovery path in H2?
ATS Order Sustainability
The 23% ATS jump is impressive. Is this driven by a specific customer rollout (e.g., AI packaging) that might be lumpy, or do you see this run-rate persisting throughout FY26?